{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:57:06Z","timestamp":1781801826189,"version":"3.54.5"},"reference-count":32,"publisher":"American Diabetes Association","issue":"4","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Expenditures on glucose-lowering prescriptions may have changed because of the introduction of new medication classes and changes in insurance policies. This study analyzed national trends in per capita expenditures on glucose-lowering medications among U.S. adults with diabetes during 2000\u20132022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>Using Medical Expenditure Panel Surveys data, we analyzed annual per capita expenditures on glucose-lowering medications among people aged \u226518 years with self-reported diabetes. Expenditures were calculated overall and by subgroups defined by age, race and ethnicity, income, and insurance status. Medications were grouped as older oral agents (metformin, sulfonylureas, thiazolidinediones, \u03b1-glucosidase inhibitors, meglitinides), newer noninsulin agents (dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists, sodium\u2013glucose cotransporter 2 inhibitors, amylin analogs, combination products), human insulin, and analog insulin. Joinpoint regression was used to identify trend changes. We also estimated the change in number of users and expenditure per user for each medication category. Expenditures were adjusted to 2022 U.S. dollars.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Total per capita expenditures on glucose-lowering medications increased by 335%, from $856 in 2000 to $3,725 in 2022. Expenditures rose by $29 per year during 2000\u20132012, then accelerated by $224 annually. Expenditures increased substantially on newer noninsulin agents while declining on older oral agents, and human insulin expenditures declined. Analog insulin expenditures rose initially but plateaued after 2016. The upward trend in newer high-cost therapies was primarily driven by an increased number of users.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Per capita expenditures on newer medications have risen markedly. Identifying key drivers of these expenditures may enhance affordability and access to effective diabetes treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc25-2016","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T17:38:36Z","timestamp":1771349916000},"page":"571-577","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":0,"title":["National Trends in Expenditures on Glucose-Lowering Medications in U.S. Adults With Diabetes: 2000\u20132022"],"prefix":"10.2337","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4740-6406","authenticated-orcid":false,"given":"Yu","family":"Wang","sequence":"first","affiliation":[{"name":"Division of Diabetes Translation, Centers for Disease Control and Prevention , Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai McKeever","family":"Bullard","sequence":"additional","affiliation":[{"name":"Division of Diabetes Translation, Centers for Disease Control and Prevention , Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Diabetes Translation, Centers for Disease Control and Prevention , Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"2026061812263347800_B1","unstructured":"Centers for Disease Control and Prevention\n          . National Diabetes Statistics Report, 2024. Accessed 15 September 2025. Available from https:\/\/www.cdc.gov\/diabetes\/php\/data-research\/index.html"},{"key":"2026061812263347800_B2","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jama.2024.26790","article-title":"Tracking US health care spending by health condition and county","volume":"333","author":"Dieleman","year":"2025","journal-title":"JAMA"},{"key":"2026061812263347800_B3","doi-asserted-by":"crossref","first-page":"112154","DOI":"10.1016\/j.diabres.2025.112154","article-title":"National trends in per-capita medical expenditures among U.S. adults with diabetes, 2000\u20132022","volume":"223","author":"Tang","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"2026061812263347800_B4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2213-8587(20)30343-0","article-title":"Guideline recommendations and the positioning of newer drugs in type 2 diabetes care","volume":"9","author":"Marx","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026061812263347800_B5","doi-asserted-by":"crossref","first-page":"108625","DOI":"10.1016\/j.jdiacomp.2023.108625","article-title":"Utilization and impact of SLGT2 inhibitors among diabetes patients in a nationally representative survey: findings from NHANES 2013\u20132020","volume":"37","author":"Shen","year":"2023","journal-title":"J Diabetes Complications"},{"key":"2026061812263347800_B6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.japh.2023.10.002","article-title":"Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022","volume":"64","author":"Watanabe","year":"2024","journal-title":"J Am Pharm Assoc (2003)"},{"key":"2026061812263347800_B7","unstructured":"Amin\n              K\n            , TelesfordI, SinghR. How do prices of drugs for weight loss in the US compare to peer nations\u2019 prices?KFF Health System Tracker, 17 August2023. Accessed 15 September 2025. Available from https:\/\/www.healthsystemtracker.org\/brief\/prices-of-drugs-for-weight-loss-in-the-us-and-peer-nations\/"},{"key":"2026061812263347800_B8","unstructured":"Cubanski\n              J\n            , NeumanT. Medicare spending on Ozempic and other GLP-1s is skyrocketing. KFF, 22 March2024. Accessed 15 September 2025. Available from https:\/\/www.kff.org\/health-costs\/medicare-spending-on-ozempic-and-other-glp-1s-is-skyrocketing\/"},{"key":"2026061812263347800_B9","unstructured":"Williams\n              E\n            , RudowitzR, BellC. Medicaid coverage of and spending on GLP-1s. KFF, 4 November2024. Accessed 15 September 2025. Available from https:\/\/www.kff.org\/medicaid\/medicaid-coverage-of-and-spending-on-glp-1s\/"},{"key":"2026061812263347800_B10","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.2337\/dc19-2273","article-title":"Factors contributing to the rising national cost of glucose-lowering medicines for diabetes during 2005\u20132007 and 2015\u20132017","volume":"43","author":"Zhou","year":"2020","journal-title":"Diabetes Care"},{"key":"2026061812263347800_B11","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1377\/hlthaff.2023.01592","article-title":"Colorado insulin copay cap: lower out-of-pocket payments, increased prescription volume and days\u2019 supply: article examines Colorado\u2019s insulin copay cap law","volume":"43","author":"Ukert","year":"2024","journal-title":"Health Aff"},{"key":"2026061812263347800_B12","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1377\/hlthaff.2024.00118","article-title":"State out-of-pocket caps on insulin costs: no significant increase in claims or utilization","volume":"43","author":"Anderson","year":"2024","journal-title":"Health Aff (Millwood)"},{"key":"2026061812263347800_B13","doi-asserted-by":"crossref","first-page":"439","DOI":"10.7326\/M23-1965","article-title":"Association of state insulin out-of-pocket caps with insulin cost-sharing and use among commercially insured patients with diabetes: a pre\u2013post study with a control group","volume":"177","author":"Garabedian","year":"2024","journal-title":"Ann Intern Med"},{"key":"2026061812263347800_B14","doi-asserted-by":"crossref","first-page":"e210313","DOI":"10.1001\/jamahealthforum.2021.0313","article-title":"Access to affordable insulin and epinephrine autoinjectors through federally qualified health centers","volume":"2","author":"Rangavajla","year":"2021","journal-title":"JAMA Health Forum"},{"key":"2026061812263347800_B15","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1001\/jama.2016.0126","article-title":"Expenditures and prices of antihyperglycemic medications in the United States: 2002\u20132013","volume":"315","author":"Hua","year":"2016","journal-title":"JAMA"},{"key":"2026061812263347800_B16","unstructured":"Agency for Healthcare Research and Quality\n          . MEPS HC 243: 2022 full year consolidated data file,2024. Accessed 18 October 2024. Available from https:\/\/meps.ahrq.gov\/data_stats\/download_data\/pufs\/h243\/h243doc.shtml"},{"key":"2026061812263347800_B17","unstructured":"Agency for Healthcare Research and Quality\n          . MEPS HC-229A: 2021 prescribed medicines, 2024. Accessed 21 February 2024. Available from https:\/\/meps.ahrq.gov\/data_stats\/download_data\/pufs\/h229a\/h229adoc.shtml#Methodology252"},{"key":"2026061812263347800_B18","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2337\/dc20-2871","article-title":"Trends in total and out-of-pocket payments for noninsulin glucose-lowering drugs among U.S. adults with large-employer private health insurance from 2005 to 2018","volume":"44","author":"Shao","year":"2021","journal-title":"Diabetes Care"},{"key":"2026061812263347800_B19","unstructured":"Agency for Healthcare Research and Quality\n          . Medical Expenditure Panel Survey, 2023. Accessed 20 January 2025. Available from https:\/\/meps.ahrq.gov\/mepsweb\/"},{"key":"2026061812263347800_B20","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z","article-title":"Permutation tests for joinpoint regression with applications to cancer rates","volume":"19","author":"Kim","year":"2000","journal-title":"Statist Med"},{"key":"2026061812263347800_B21","unstructured":"Agency for Healthcare Research and Quality\n          . Using appropriate price indices for analyses of health care expenditures or income across multiple years, 2024. Accessed 20 January 2025. Available from https:\/\/meps.ahrq.gov\/about_meps\/Price_Index.shtml"},{"key":"2026061812263347800_B22","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.2337\/dc19-S011","article-title":"11. Microvascular complications and foot care: Standards of Medical Care in Diabetes\u20142019","volume":"42","author":"American Diabetes Association","year":"2019","journal-title":"Diabetes Care"},{"key":"2026061812263347800_B23","first-page":"520","article-title":"Trends in first-line glucose-lowering medication use among US adults with type 2 diabetes from 2019 to 2023","volume":"31","author":"Do","year":"2025","journal-title":"J Manag Care Spec Pharm"},{"key":"2026061812263347800_B24","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.sapharm.2024.01.004","article-title":"Why the increase? Examining the rise in prescription medication expenditures in the United States between 2011 and 2020","volume":"20","author":"Chi","year":"2024","journal-title":"Res Social Adm Pharm"},{"key":"2026061812263347800_B25","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/oby.23652","article-title":"Trends in obesity prevalence and cardiometabolic risk factor control in US adults with diabetes, 1999\u20132020","volume":"31","author":"Hu","year":"2023","journal-title":"Obesity (Silver Spring)"},{"key":"2026061812263347800_B26","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1377\/hlthaff.2018.0154","article-title":"Medicaid eligibility expansions may address gaps in access to diabetes medications","volume":"37","author":"Myerson","year":"2018","journal-title":"Health Aff (Millwood)"},{"key":"2026061812263347800_B27","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jamainternmed.2015.4338","article-title":"Trends in Medicaid reimbursements for insulin from 1991 through 2014","volume":"175","author":"Luo","year":"2015","journal-title":"JAMA Intern Med"},{"key":"2026061812263347800_B28","first-page":"154","article-title":"Differences between managed care and fee-for-service Medicaid in the use of generics for high-rebate drugs: the cases of insulin glargine and glatiramer","volume":"26","author":"Hernandez","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"2026061812263347800_B29","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/S0140-6736(21)02402-8","article-title":"Origins of the insulin crisis: how a century of price-fixing controversies affects the cost of care today","volume":"398","author":"Strodel","year":"2021","journal-title":"The Lancet"},{"key":"2026061812263347800_B30","unstructured":"Sayed\n              BA\n            , FinegoldK, OlsenTA, . Insulin affordability and the Inflation Reduction Act: Medicare beneficiary savings by state and demographics, 2023. Accessed 15 September 2025. Available from https:\/\/aspe.hhs.gov\/reports\/insulin-affordability-ira-data-point"},{"key":"2026061812263347800_B31","unstructured":"Zodet\n              MW\n            , HillSC, MillerE. Comparison of retail drug prices in the MEPS and MarketScan: implications for MEPS editing rules, 2010. Accessed 15 September 2025. Available from https:\/\/meps.ahrq.gov\/data_files\/publications\/workingpapers\/wp_10001.pdf"},{"key":"2026061812263347800_B32","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.2337\/dc13-1997","article-title":"Changes over time in high out-of-pocket health care burden in U.S. adults with diabetes, 2001\u20132011","volume":"37","author":"Li","year":"2014","journal-title":"Diabetes Care"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/49\/4\/571\/857122\/dc252016.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/49\/4\/571\/857122\/dc252016.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:26:43Z","timestamp":1781800003000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/49\/4\/571\/164500\/National-Trends-in-Expenditures-on-Glucose"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2,17]]},"published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc25-2016","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]}}}